[Appropriate administration of granulocyte colony stimulating factor for malignant lymphoma of the head and neck].
The effects of granulocyte colony stimulating factor (G-CSF) were evaluated in 9 patients with malignant lymphoma of the head and neck. The effects of 31 cycles of cytotoxic chemotherapy were treated with G-CSF. G-CSF was given by one of the following three routes: 1) administration before or with cytotoxic chemotherapy, 2) administration after cytotoxic chemotherapy with leukocyte counts of more than 2000/mm3, and 3) administration after leukocyte counts had dropped to less than 2000/mm3. The first group consisted of one cycle of CHOP therapy and 2 cycles of VAMA therapy. The second group consisted of 10 cycles of CHOP therapy. The third group consisted of 13 cycles of CHOP therapy and 5 cycles of VAMA therapy. Leukocyte nadirs occurred on around day 14 for CHOP therapy and around day 21 for VAMA therapy without G-CSF treatment. In the first group, the leukocyte nadirs occurred earlier with G-CSF treatment. Additional G-CSF treatments were given in two of the three cycles. In the second group, the leukocyte counts did not drop below 2000/mm3 in three of the ten cycles. Additional G-CSF treatments were given in five of the remaining seven cycles. The two other cycles went without additional treatment. The mean volume of G-CSF was 305 +/- 86 micrograms. In the third group, the leukocyte counts increased to more than 2000/mm3 immediately after G-CSF administration in CHOP therapy. The mean volume was 227 +/- 78 micrograms, significantly less than that of the second group. The leukocyte counts also exceeded 2000/mm3 3-5 days after G-CSF administration in 5 cycles of VAMA therapy.(ABSTRACT TRUNCATED AT 250 WORDS)
Miyaguchi
M
M
Department of Otolaryngology, Kagawa Medical School.
Takeda
J
J
Furuta
H
H
Uozumi
N
N
Miyabe
K
K
Sakai
S
S
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects; D001215:Asparaginase / Q000009:adverse effects; D003520:Cyclophosphamide / Q000009:adverse effects; D003561:Cytarabine / Q000009:adverse effects; D004317:Doxorubicin / Q000009:adverse effects; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage* / Q000627:therapeutic use; D006258:Head and Neck Neoplasms / Q000188:drug therapy / Q000628:therapy*; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced / Q000628:therapy; D008223:Lymphoma / Q000188:drug therapy / Q000628:therapy*; D008727:Methotrexate / Q000009:adverse effects; D011241:Prednisone / Q000009:adverse effects; D013713:Teniposide / Q000009:adverse effects; D014750:Vincristine / Q000009:adverse effects
D003561:Cytarabine; D016179:Granulocyte Colony-Stimulating Factor; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D013713:Teniposide; D001215:Asparaginase; D011241:Prednisone; D008727:Methotrexate